Literature DB >> 15090872

Ménière's disease.

Lloyd B Minor1, David A Schessel, John P Carey.   

Abstract

PURPOSE OF REVIEW: Ménière's disease is characterized by spontaneous attacks of vertigo, fluctuating sensorineural hearing loss, aural fullness, and tinnitus. The pathologic process involves distortion of the membranous labyrinth with the formation of endolymphatic hydrops. This review describes the pathogenesis and etiology as well as the diagnosis and treatment of Ménière's disease. RECENT
FINDINGS: Initial management of Ménière's disease can involve a low-salt diet and a diuretic. Treatment with intratympanic injection of gentamicin can be beneficial when vertigo persists despite optimal medical management. Recent studies have shown that gentamicin reduces vestibular function in the treated ear, although complete ablation of this vestibular function is not typically required in order to achieve control of vertigo.
SUMMARY: Vertigo is often the most debilitating symptom associated with Ménière's disease. Many treatment options exist for the management of vertigo. Intratympanic injection of gentamicin (low dose) can be used in patients for whom vertigo has not been controlled by medical measures. Ongoing research is providing a greater understanding of the effects of gentamicin on vestibular function and of the mechanisms through which gentamicin leads to control of vertigo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15090872     DOI: 10.1097/00019052-200402000-00004

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  43 in total

1.  Current treatment of vestibular, ocular motor disorders and nystagmus.

Authors:  Michael Strupp; Thomas Brandt
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

2.  Successful treatment of a child with definite Meniere's disease with the migraine regimen.

Authors:  Mehdi Abouzari; Arash Abiri; Hamid R Djalilian
Journal:  Am J Otolaryngol       Date:  2019-02-18       Impact factor: 1.808

Review 3.  Vertigo and dizziness in the emergency department.

Authors:  Kevin A Kerber
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

4.  Preclinical and clinical studies of unrelieved aural fullness following intratympanic gentamicin injection in patients with intractable Ménière's disease.

Authors:  Feng Zhai; Ru Zhang; Ting Zhang; Peter S Steyger; Chun-Fu Dai
Journal:  Audiol Neurootol       Date:  2013-08-30       Impact factor: 1.854

5.  Vitamin D supplementation may improve symptoms in Meniere's disease.

Authors:  Bela Büki; Heinz Jünger; Yunxia Wang Lundberg
Journal:  Med Hypotheses       Date:  2018-04-24       Impact factor: 1.538

6.  Surgical indication in Menière's disease therapy: clinical and epidemiological aspects.

Authors:  Roberto Albera; Andrea Canale; Fiorella Parandero; Alessandro Ducati; Michele Lanotte
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-19       Impact factor: 2.503

7.  Endolymphatic sac surgery versus tenotomy of the stapedius and tensor tympani muscles in the management of patients with unilateral definite Meniere's disease.

Authors:  Silviu Albu; Gregorio Babighian; Maurizio Amadori; Franco Trabalzini
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-12-07       Impact factor: 2.503

8.  Histopathological and ultrastructural analysis of vestibular endorgans in Meniere's disease reveals basement membrane pathology.

Authors:  Andrew A McCall; Gail P Ishiyama; Ivan A Lopez; Sunita Bhuta; Steven Vetter; Akira Ishiyama
Journal:  BMC Ear Nose Throat Disord       Date:  2009-06-03

9.  Immunohistochemical localization and mRNA expression of aquaporins in the macula utriculi of patients with Meniere's disease and acoustic neuroma.

Authors:  Gail Ishiyama; Ivan A Lopez; Luis Beltran-Parrazal; Akira Ishiyama
Journal:  Cell Tissue Res       Date:  2010-05-12       Impact factor: 5.249

10.  Neuropharmacology of vestibular system disorders.

Authors:  Enrique Soto; Rosario Vega
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.